NYSE$CHE

Chemed Corp · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Chemed reported solid Q4 2024 financial results, driven by strong performance in the VITAS segment.

Chemed Corporation reported Q4 2024 revenue of $640.0 million, an increase of 9.2% year-over-year. Net income attributable to common stock was $90.3 million, with EPS of $6.02 and adjusted EPS of $6.83. VITAS segment revenue grew 17.4%, while Roto-Rooter saw a slight revenue decline. Free cash flow remained strong, and the company repurchased shares worth $212.8 million.

  • Revenue increased 9.2% to $640.0 million.
  • Net income attributable to common stock was $90.3 million.
  • EPS reached $6.02, with adjusted EPS at $6.83.
  • VITAS revenue grew 17.4%, while Roto-Rooter declined 2.9%.

Headline financials

Total Revenue

$640M

Previous: $586M+9.2%
EPS (adj)

$6.83

Previous: $6.60+3.5%
Average Daily Census

22.2K

Previous: 19.4K+14.6%
VITAS Admissions

16.4K

Previous: 15.9K+3.5%
VITAS Adjusted EBITDA

$93.2M

No prior period
Roto-Rooter Adjusted EBITDA

$60.3M

No prior period
VITAS Gross Margin

28.8%

No prior period
Roto-Rooter Gross Margin

51.3%

No prior period
Net Income

$90.3M

Previous: $90.1M+0.3%
Operating Income

$114M

Previous: $111M+2.2%

Revenue & EPS history

Chemed · Revenue · Quarterly

$640M

Q4 2024+9.2%vs Q4 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Chemed · $565M total across 2 segments · Q3 2023

  • VITAS Healthcare
    $334M+12.4%
  • Roto-Rooter
    $231M+0.3%

Forward guidance

Chemed anticipates continued growth in 2025, with VITAS revenue expected to rise by 10.5% to 11.3% and Roto-Rooter revenue projected to grow by 2.4% to 3.0%. Adjusted EPS is estimated to be between $24.95 and $25.45.

Tailwinds

  • VITAS revenue expected to grow between 10.5% and 11.3%.
  • Roto-Rooter revenue projected to increase between 2.4% and 3.0%.
  • Expected full-year adjusted EBITDA margin of 18.4% to 18.9% for VITAS.
  • Medicare Cap billing limitations estimated at $9.5 million.
  • Strong share repurchase program with $255.3 million remaining authorization.

Headwinds

  • Medicare Cap rate increase lower than reimbursement rate increase, reducing cushion.
  • Roto-Rooter revenue growth expected to be slower in early 2025.
  • Higher costs expected due to ongoing expansion in VITAS.
  • Potential impact from labor market constraints in healthcare and plumbing sectors.
  • Economic uncertainty may impact demand for non-essential services.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.7%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+2.1%

Avg return

30 days after

53%

36 / 68 earnings

Positive

+13.0%

Q3 2015

Best reaction

-14.8%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-0.1%+4.0%
Q4 2025-14.8%-9.1%-21.0%
Q3 2025+6.0%+0.4%+0.1%
Q1 2025-6.6%-1.8%-2.7%
Q4 2024+7.4%+7.7%+11.0%
Q3 2024-12.0%-12.7%-6.2%
Q2 2024-0.1%+2.4%+5.7%
Q1 2024-7.0%-8.1%-9.9%
Q4 2023+5.1%+2.6%+7.3%
Q3 2023+9.3%+10.9%+14.4%
Q2 2023-8.1%-8.0%-10.8%
Q1 2023-3.7%-2.2%-4.1%
Q4 2022+3.3%+1.7%+1.9%
Q3 2022+3.2%+4.1%+12.6%
Q2 2022-6.8%-9.2%-8.3%
Q1 2022-1.4%-1.0%+0.8%
Q4 2021+5.1%+5.8%+3.8%
Q3 2021+9.2%+9.0%+9.4%
Q2 2021-4.4%-0.4%-2.4%
Q1 2021+1.5%+2.3%+6.1%
Q4 2020-0.8%-6.7%-3.9%
Q3 2020+1.2%+3.5%+0.2%
Q2 2020+9.0%+10.3%+12.2%
Q1 2020-3.9%-6.5%+5.6%
Q4 2019+3.2%-1.2%-23.1%
Q3 2019-1.7%+0.6%+5.9%
Q2 2019+3.7%+8.1%+13.9%
Q1 2019-0.6%+0.7%+0.3%
Q4 2018+1.3%+2.8%+1.9%
Q3 2018+6.2%+6.6%+7.6%
Q2 2018+0.4%-2.5%+0.1%
Q1 2018+3.0%+3.3%+13.4%
Q4 2017+2.4%+2.1%+12.9%
Q3 2017+9.1%+5.0%+12.7%
Q2 2017-1.1%-2.3%-6.3%
Q1 2017+10.0%+9.4%+9.0%
Q4 2016+1.9%+2.0%+9.1%
Q3 2016-0.3%+1.8%+6.3%
Q2 2016+5.0%+3.0%-7.9%
Q1 2016-6.7%
Q4 2015-5.6%
Q3 2015+13.0%
Q2 2015+5.1%
Q1 2015-4.7%
Q4 2014+7.5%
Q3 2014-1.2%
Q2 2014+4.3%
Q1 2014-3.3%
Q4 2013+10.5%
Q3 2013-5.2%
Q2 2013-7.3%
Q1 2013+3.4%
Q4 2012+4.9%
Q3 2012-2.0%
Q2 2012+5.1%
Q1 2012+2.9%
Q4 2011+0.0%
Q3 2011+1.5%
Q2 2011-5.8%
Q1 2010-2.6%
Q1 2011+1.8%
Q4 2008-1.6%
Q4 2010-1.6%
Q3 2009+1.4%
Q3 2010+1.4%
Q2 2010-0.9%
Q2 2009-0.9%
Q4 2009-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro